These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4768206)

  • 41. Current concepts in the management of Parkinson's disease.
    Chapman WG
    West Indian Med J; 1974 Mar; 23(1):61-4. PubMed ID: 4456821
    [No Abstract]   [Full Text] [Related]  

  • 42. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 44. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of Parkinson's disease: L-dopa or stereotaxic technics?].
    Krayenbuhl H; Siegfried J
    Neurochirurgie; 1970; 16(1):71-6. PubMed ID: 4911157
    [No Abstract]   [Full Text] [Related]  

  • 46. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
    Birkmayer W
    Wien Klin Wochenschr; 1969 Sep; 81(39):677-9. PubMed ID: 5344299
    [No Abstract]   [Full Text] [Related]  

  • 48. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Nervenarzt; 1977 Apr; 48(4):205-10. PubMed ID: 404579
    [No Abstract]   [Full Text] [Related]  

  • 49. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1969 Dec; 197(1):85-100. PubMed ID: 5364658
    [No Abstract]   [Full Text] [Related]  

  • 50. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 51. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A
    Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
    [No Abstract]   [Full Text] [Related]  

  • 52. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 53. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 54. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

  • 55. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 56. [L-dopa in the treatment of the Parkinsonian syndrome].
    Apostol-Pruskauer B; Voiculescu V
    Neurol Psihiatr Neurochir; 1973; 18(6):539-49. PubMed ID: 4790486
    [No Abstract]   [Full Text] [Related]  

  • 57. [Aspects of hypersexuality observed in parkinsonian patients treated by L-dopa].
    Ballivet J; Marin A; Gisselmann A
    Ann Med Psychol (Paris); 1973 Nov; 2(4):515-22. PubMed ID: 4799646
    [No Abstract]   [Full Text] [Related]  

  • 58. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 59. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 60. [Medical treatment of Parkinson's disease].
    Castaigne P; Rondot P; Ribadeau-Dumas JL
    Ann Med Interne (Paris); 1972 Apr; 123(4):357-64. PubMed ID: 5077040
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.